Ligand Pharmaceuticals Incorporated re-affirmed earnings guidance for 2024. For the period, the company reaffirms total revenue forecast of $130 million to $142 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.22 USD | +0.54% | +4.76% | +2.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.52% | 1.31B | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024